Key result
Ticagrelor lowers 30-day platelet reactivity by ~17 U compared to clopidogrel.
Why the study?
Platelet counts and characteristics can influence platelet reactivity during antiplatelet therapy, motivating a comparison of the effects of platelet count and indices on platelet reactivity between patients treated with clopidogrel or ticagrelor.
RCT (n=128)
1:1 randomization
No
Answers are grounded in this paper and cite their sources.
Ticagrelor may offer greater platelet inhibition than clopidogrel; hypothesis-generating for platelet indices and requires outcome trials before practice change.
Background/Aims: Platelet counts and characteristics can influence platelet reactivity during antiplatelet therapy.We compared the effects of both platelet count and indices on platelet reactivity between patients who were treated with either clopodogrel or ticagrelor.Methods: Patients with coronary artery disease who underwent percutaneous coronary intervention were randomly assigned to either the clopidogrel (n = 63) or ticagrelor (n = 65) groups.Platelet count, platelet indices (including mean platelet volume, platelet distribution width, platelet large cell ratio, and immature platelet fraction), and platelet reactivity were measured before intervention, and 48 hours and 30 days post-intervention.High on-treatment platelet reactivity (HPR) was defined as ≥ 47 unit as assessed by multiple electrode platelet aggregometry.Results: Baseline platelet reactivity was similar between the two groups; however, at 48 hours and 30 days, platelet reactivity was significantly lower in the ticagrelor group than in the clopidogrel group.Platelet count, mean platelet volume, platelet distribution width, platelet large cell ratio, and immature platelet fraction were significantly correlated with platelet reactivity in the clopidogrel group; however, these correlations were attenuated in the ticagrelor group.The use of clopodogrel (hazard ratio [HR] 4.1, 95% confidence interval [CI] 1.4-11.9;p = 0.010) and platelet count (HR 9.7, 95% CI 2.9-32.7;p = 0.001) were independent predictors for 30 day HPR.Platelet count was an independent predictor of HPR in the clopidogrel group but not in the ticagrelor group.Conclusions: Platelet count and indices are significantly correlated with platelet reactivity.However, antiplatelet treatment with ticagrelor could overcome these associations.(Korean J Med 2017;92:526-532)
No takes yet. Share an insight, caveat, or question.
Yun et al. (2017) conducted an RCT in Coronary artery disease undergoing percutaneous coronary intervention (PCI) (n=128). Ticagrelor vs. Clopidogrel (loading dose followed by 75 mg/day maintenance) was evaluated on 30-day platelet reactivity (MEA ADP test, units) (p=<0.001). Ticagrelor lowered 30-day platelet reactivity compared to clopidogrel and attenuated the correlation between platelet count/indices and platelet reactivity.
Synapse has enriched 10 related papers. Consider them for comparative context: